Syntenin-1 Exosome Biogenesis Modulation Therapy for Neurodegeneration
10-Dimension Rubric Scoring
Mermaid diagram (expand to render)
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 9/10 | First therapeutic targeting Syntenin-1/exosome biogenesis pathway; no existing therapies target this upstream exosome formation mechanism | | Mechanistic Rationale | 8/10 | Strong mechanistic link: Syntenin-1 acts as master scaffold for ALIX-dependent exosome biogenesis; alpha-syn, tau, TDP-43 all shown to propagate via exosomes | | Root-Cause Coverage | 7/10 | Addresses upstream mechanism of pathogenic protein secretion rather than downstream aggregation; reduces exosomal propagation burden | | Delivery Feasibility | 7/10 | Small molecule inhibitors or peptide blockers could cross BBB; AAV-mediated shRNA possible but requires optimization | | Safety Plausibility | 7/10 | Exosome biogenesis inhibition must be carefully titrated to avoid impairing normal neuronal communication; therapeutic window exists | | Combinability | 8/10 | Synergizes with aggregation inhibitors, autophagy enhancers, and microglia modulators; addresses secretion component of proteostasis | | Biomarker Availability | 6/10 | Exosomal protein cargo (p-tau, alpha-syn, TDP-43) in CSF/blood as pharmacodynamic markers; Syntenin-1 levels in extracellular vesicles | | De-risking Path | 7/10 | In vitro proof in neuron cultures, ex vivo patient-derived iPSC neurons, then IND-enabling studies; clear readouts available | | Multi-disease Potential | 9/10 | Core mechanism relevant to AD (tau exosomal spread), PD (alpha-syn exosomal spread), ALS (TDP-43 exosomal spread), FTD (TDP-43/tau) | | Patient Impact | 8/10 | Addresses progressive spread of pathology; could slow disease progression in early-to-moderate stage patients |
Total Score: 76/100
Disease Coverage Matrix
| Disease | Coverage Score | Rationale | |---------|----------------|-----------| | Alzheimer's Disease | 9 | Tau propagation via exosomes well-documented; Syntenin-1 modulates this pathway | | Parkinson's Disease | 9 | α-Synuclein secreted via exosomes; Syntenin-1 inhibition reduces burden | | ALS | 8 | TDP-43 and SOD1 exported in exosomes; pathway relevance established | | FTD | 8 | TDP-43 and tau propagation; shared exosomal mechanisms | | Aging | 7 | Exosome biogenesis dysregulation with age; contributes to proteostatic decline |
Category
Novel target (exosome biogenesis)
Therapeutic Target
Primary Target: Syntenin-1 (SDCBP)
Syntenin-1 (also known as SDCBP) is a small PDZ domain-containing scaffold protein that plays a critical role in exosome biogenesis by recruiting ALIX to intraluminal vesicles (ILVs) in multivesicular bodies (MVBs).
Secondary Targets
ALIX (PD6A) — Essential cofactor for Syntenin-1-dependent exosome formation
ESCRT-III subunits (CHMP4B/C, CHMP2A) — Downstream effectors of exosome release
RAB27A/B — Regulators of MVB docking and exosome release (alternative pathway)
Key Mechanism
The Syntenin-ALIX Exosome Biogenesis Pathway
Syntenin-1 Recruitment: Syntenin-1 binds to phosphatidylinositol-4,5-bisphosphate (PIP2) on endosomal membranes via its N-terminal domain
ALIX Recruitment: Syntenin-1's PDZ domains recruit ALIX (also known as PD6A) through direct protein-protein interaction
RNAi/shRNA — Reduce Syntenin-1 expression via AAV-delivered constructs
Evidence for Therapeutic Relevance
[Roux et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16543458/) — Original identification of Syntenin-1 as ALIX interactor via BioID
[Baietti et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22903299/) — Demonstrated Syntenin-SPDP is required for exosome biogenesis in HeLa cells
[Larios et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32439764/) — Confirmed ALIX- and ESCRT-III-dependent sorting of transmembrane proteins into exosomes
[Gauthier et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28733926/) — Phosphorylated tau interacts with endosomal system and is secreted in exosomes
[Emmanouilidou et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21177974/) — Cell-produced α-syn is secreted in exosomes in a calcium-dependent manner
[Schneider & Simons, 2016](https://pubmed.ncbi.nlm.nih.gov/27797869/) — Exosomes as vehicle for tau propagation between neurons
Rationale
Why This Target?
Upstream Mechanism: Unlike downstream aggregation inhibitors, this approach reduces the production of pathogenic exosomes at source
Genetic Validation: SDCBP (Syntenin-1) is widely expressed in neurons and glia; no known loss-of-function disease mutations suggest therapeutic inhibition is tolerable
Broad Disease Relevance: All major neurodegenerative proteinopathies involve exosomal propagation
Proof-of-Concept: Studies show reducing exosome release decreases pathological spreading in cell and animal models